Published in PLoS One on March 16, 2017
Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA (2000) 55.37
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 42.90
Cancer statistics, 2016. CA Cancer J Clin (2016) 32.95
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol (2010) 16.24
-Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol (2015) 4.31
Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol (2006) 3.83
Sociodemographic factors and delays in the diagnosis of six cancers: analysis of data from the "National Survey of NHS Patients: Cancer". Br J Cancer (2005) 2.91
Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol (2006) 2.38
Racial differences in diagnosis, treatment, and clinical delays in a population-based study of patients with newly diagnosed breast carcinoma. Cancer (2004) 2.38
Delays in breast cancer diagnosis and treatment by racial/ethnic group. Arch Intern Med (2006) 2.32
Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women. Breast Cancer Res Treat (2006) 2.26
Determinants of three stages of delay in seeking care at a medical clinic. Med Care (1979) 2.24
Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol (2000) 1.81
Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol (2014) 1.68
Black-white differences in receipt and completion of adjuvant chemotherapy among breast cancer patients in a rural region of the US. Breast Cancer Res Treat (2012) 1.65
Hospital-associated costs due to surgical site infection after breast surgery. Arch Surg (2008) 1.62
Delays in adjuvant chemotherapy treatment among patients with breast cancer are more likely in African American and Hispanic populations: a national cohort study 2004-2006. J Clin Oncol (2010) 1.58
Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG). Br J Cancer (2005) 1.52
Transportation as a barrier to cancer treatment. Cancer Pract (1997) 1.35
Breast cancer control among the underserved--an overview. Breast Cancer Res Treat (1996) 1.32
The impact of breast reconstruction on the delivery of chemotherapy. Cancer (2010) 1.20
Narrowing racial gaps in breast cancer chemotherapy initiation: the role of the patient-provider relationship. Breast Cancer Res Treat (2013) 1.00
Racial/Ethnic differences in receipt of timely adjuvant therapy for older women with breast cancer: are delays influenced by the hospitals where patients obtain surgical care? Health Serv Res (2013) 0.95
Black Medicaid beneficiaries experience breast cancer treatment delays more frequently than whites. Ethn Dis (2012) 0.90
Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: a negative outcome study by the Spanish Breast Cancer Research Group (GEICAM). Breast Cancer Res Treat (2006) 0.88
Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer. Acta Oncol (2013) 0.87
Delay of adjuvant chemotherapy after elective mastectomy and immediate reconstruction in breast-conservation candidates: a matched-pair analysis. Am J Clin Oncol (2014) 0.86
Ethnic differences in timely adjuvant chemotherapy and radiation therapy for breast cancer in New Zealand: a cohort study. BMC Cancer (2014) 0.85
Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials. Psychooncology (2011) 0.84
Socioeconomic deprivation and inpatient complication rates following mastectomy and breast reconstruction surgery. Br J Surg (2015) 0.80
The effect of immediate breast reconstruction on the timing of adjuvant chemotherapy: a systematic review. Breast Cancer Res Treat (2015) 0.80
A systematic review of the influence of occupational organophosphate pesticides exposure on neurological impairment. BMJ Open (2014) 0.79
Racial differences in the use of adjuvant chemotherapy for breast cancer in a large urban integrated health system. Int J Breast Cancer (2012) 0.79
Adjuvant chemotherapy in early breast cancer. Dan Med J (2016) 0.77
The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat (2016) 0.77
miR-200c inhibits breast cancer proliferation by targeting KRAS. Oncotarget (2015) 0.90
miR-26a suppresses tumour proliferation and metastasis by targeting metadherin in triple negative breast cancer. Cancer Lett (2014) 0.89
MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer. Oncotarget (2015) 0.87
A Review: The Pharmacology of Isoliquiritigenin. Phytother Res (2015) 0.83
Development and validation of a prognostic nomogram based on the log odds of positive lymph nodes (LODDS) for breast cancer. Oncotarget (2016) 0.83
High expression of microRNA-183/182/96 cluster as a prognostic biomarker for breast cancer. Sci Rep (2016) 0.76
The Practicability of a Novel Prognostic Index (PI) Model and Comparison with Nottingham Prognostic Index (NPI) in Stage I-III Breast Cancer Patients Undergoing Surgical Treatment. PLoS One (2015) 0.75
Development and validation of a nomogram for predicting survival on the base of modified lymph node ratio in breast cancer patients. Breast (2017) 0.75